PMID- 15017629
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20191108
IS  - 1542-3565 (Print)
IS  - 1542-3565 (Linking)
VI  - 2
IP  - 1
DP  - 2004 Jan
TI  - Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter 
      pylori by triple therapy.
PG  - 22-30
AB  - BACKGROUND AND AIMS: Polymorphism in interleukin-1beta (IL-1beta) is associated 
      with intragastric pH levels in Helicobacter pylori-positive subjects. 
      Intragastric pH levels affect the activity of antibiotics against H. pylori in 
      the stomach. The aim of this study was to investigate whether IL-1beta 
      polymorphism is associated with eradication rates of H. pylori by triple therapy 
      with a proton pump inhibitor (PPI), amoxicillin, and clarithromycin. METHODS: 
      Three hundred thirty-six patients infected with H. pylori completed treatment 
      with omeprazole, 20 mg, or lansoprazole, 30 mg twice daily; clarithromycin, 200 
      mg 3 times daily; and amoxicillin, 500 mg 3 times daily, for 1 week. IL-1beta-511 
      and CYP2C19 genotypes of patients and sensitivity of H. pylori to clarithromycin 
      and amoxicillin were determined. RESULTS: Logistic regression analysis showed 
      that the IL-1beta-511 polymorphism, as well as CYP2C19 genotype of patients and 
      clarithromycin-resistance of H. pylori, was associated with successful 
      eradication. Eradication rates for H. pylori were 77.3% (75 of 97; 95% confidence 
      interval, 67.5-84.6), 89.6% (147 of 164; 95% confidence interval, 83.9-93.1), and 
      94.7% (95% confidence interval, 86.9-98.5) in patients with the C/C, C/T, and T/T 
      genotypes of IL-1beta-511, respectively (P = 0.0014). CONCLUSIONS: IL-1beta-511 
      polymorphism is one of the determinants of successful eradication of H. pylori 
      using triple therapy with a PPI, amoxicillin, and clarithromycin, together with 
      CYP2C19 genotype and bacterial resistance to clarithromycin.
FAU - Furuta, Takahisa
AU  - Furuta T
AD  - First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1, 
      Handa-Yama, Hamamatsu 431-3192, Japan. furuta@hama-med.ac.jp
FAU - Shirai, Naohito
AU  - Shirai N
FAU - Xiao, Fang
AU  - Xiao F
FAU - El-Omar, Emad M
AU  - El-Omar EM
FAU - Rabkin, Charles S
AU  - Rabkin CS
FAU - Sugimura, Haruhiko
AU  - Sugimura H
FAU - Ishizaki, Takashi
AU  - Ishizaki T
FAU - Ohashi, Kyoichi
AU  - Ohashi K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Interleukin-1)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Proton Pumps)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - H1250JIK0A (Clarithromycin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Anti-Infective Agents/therapeutic use
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Antibody Specificity/drug effects/genetics
MH  - Aryl Hydrocarbon Hydroxylases/drug effects/genetics
MH  - Clarithromycin/therapeutic use
MH  - Cytochrome P-450 CYP2C19
MH  - Drug Resistance, Multiple, Bacterial/drug effects/genetics
MH  - Drug Therapy, Combination
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastritis/genetics/microbiology
MH  - Genetic Predisposition to Disease/genetics
MH  - Genotype
MH  - Helicobacter Infections/*genetics/*microbiology
MH  - Helicobacter pylori/*drug effects/*genetics
MH  - Humans
MH  - Interleukin-1/*genetics
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Mixed Function Oxygenases/drug effects/genetics
MH  - Mutation/drug effects/genetics
MH  - Omeprazole/*analogs & derivatives/antagonists & inhibitors/therapeutic use
MH  - Patient Compliance
MH  - Peptic Ulcer/genetics/microbiology
MH  - Polymorphism, Genetic/*drug effects/*genetics
MH  - Proton Pump Inhibitors
MH  - Proton Pumps/therapeutic use
MH  - Treatment Outcome
EDAT- 2004/03/16 05:00
MHDA- 2004/04/24 05:00
CRDT- 2004/03/16 05:00
PHST- 2004/03/16 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2004/03/16 05:00 [entrez]
AID - S154235650300288X [pii]
AID - 10.1016/s1542-3565(03)00288-x [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2004 Jan;2(1):22-30. doi: 
      10.1016/s1542-3565(03)00288-x.